MMP2 and pancreatic ductal adenocarcinoma: A recent study showed that combined treatment of a MAPK inhibitor (Trametinib) and Palbociclib induced senescence and these senescent pancreatic ductal adenocarcinoma cells showed increased secretion of pro‐angiogenic factors (VEGF, PDGFA/B, and FGF2) and MMPs (MMP2/3/7/9/10) [70].